What Neumora Therapeutics does

Neumora Therapeutics, Inc. is a publicly traded (NASDAQ: NMRA) clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, with a secondary office in South San Francisco. Founded in 2019–2020, the company develops precision medicines for brain diseases across neuropsychiatric, neurodegenerative, and cardiometabolic indications, supported by its Precision Toolbox — an integrated suite of translational, clinical, and computational tools designed to enable patient stratification and target identification in central nervous system drug development. The company has raised approximately $650 million in cumulative capital since inception through private rounds and a 2023 IPO.

Neumora's pipeline comprises seven clinical and preclinical programs targeting novel mechanisms of action, including NMRA-511 (V1aR antagonist for Alzheimer's agitation), NMRA-898 (M4 muscarinic receptor positive allosteric modulator for schizophrenia), NMRA-215 (brain-penetrant NLRP3 inhibitor for obesity and cardiometabolic disease), NMRA-GCASE (for Parkinson's disease), and NMRA-CK1δ (for ALS and Parkinson's disease). The company's lead program, navacaprant — a selective kappa opioid receptor antagonist for major depressive disorder — failed to meet primary or key secondary endpoints in the Phase 3 KOASTAL-2 and KOASTAL-3 studies and was discontinued in June 2026.

The business model is pre-commercial: Neumora generates no product revenue and instead funds operations through capital markets, strategic investments (notably a $100 million Amgen investment in 2021), and disease-specific grants (including a ~$2.6 million Parkinson's UK grant in 2024). Future revenue is expected to flow through traditional pharmaceutical commercialization channels — specialty pharmacies, hospital buying groups, and direct-to-prescriber models — contingent on regulatory approval of pipeline candidates. As of FY2025 the company reported a net loss of approximately $236.9 million, with $182.5 million in cash and equivalents at year-end (declining to $147.1 million in Q1 2026) and a stated runway into Q3 2027 following a June 2026 workforce reduction of approximately 35%.

Name

Neumora Therapeutics

Legal name

Neumora Therapeutics, Inc.

Website

https://neumoratx.com/

Company type

Public

Founded year

2019

Operating status

Operating

Headcount range

101–250 employees

Short description

Neumora Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for brain diseases, including neuropsychiatric, neurodegenerative, and cardiometabolic disorders, supported by its Precision Toolbox platform; it is pre-revenue and trades on NASDAQ under NMRA.

Ownership category

akta.pro rank

Product category

Neuroscience Pharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Neuroscience drug development
• Clinical-stage biopharmaceutical
• Brain disease therapeutics
• CNS precision medicine
• Neuropsychiatric disorder treatments

Headquarters

HQ city

Watertown

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue clinical-stage biotech company. Expected to generate revenue through commercialization of pipeline candidates upon regulatory approval. Primary focus is developing and commercializing novel therapies for neuropsychiatric and neurodegenerative disorders.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Neumora Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for brain diseases, with a pipeline of seven programs targeting novel mechanisms of action in major depressive disorder, Alzheimer's disease agitation, schizophrenia, Parkinson's disease, ALS, and obesity/cardiometabolic disease. The company combines small-molecule drug candidates with its proprietary Precision Toolbox, which integrates translational, clinical, and computational tools to identify and serve patient populations most likely to respond to therapy.

Product overview

Neumora Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of precision medicines for brain diseases. The company's therapeutic pipeline consists of seven programs targeting novel mechanisms of action for neuropsychiatric disorders and neurodegenerative diseases. Lead program navacaprant is a kappa opioid receptor antagonist for major depressive disorder in Phase 3. Other programs include NMRA-511 (V1aR antagonist for Alzheimer's agitation), NMRA-898 (M4 modulator for schizophrenia), NMRA-215 (NLRP3 inhibitor for obesity), NMRA-GCASE (for Parkinson's), and NMRA-CK1δ (for ALS/Parkinson's). The pipeline is supported by the company's Precision Toolbox, which integrates translational, clinical, and computational tools to enable precision medicine approaches.

Differentiator

Problem solved

Functional benefit

Products and services

• Navacaprant (NMRA-001) A highly selective, novel kappa opioid receptor (KOR) antagonist that was in Phase 3 development as a potential once-daily oral monotherapy for major depressive disorder, designed to modulate dopamine and reward processing pathways via a non-serotonergic mechanism. Development was discontinued after Phase 3 studies failed to achieve statistical significance on primary or key secondary endpoints.
• NMRA-511 A vasopressin 1a receptor (V1aR) antagonist in development for the treatment of agitation in Alzheimer's Disease, with projected peak U.S. sales of $1.8 billion. Phase 1b data showed a 15.7-point reduction on the CMAI scale, with effect sizes of 0.51-0.64 in a pre-specified elevated-anxiety subpopulation.
• NMRA-898 An M4 muscarinic receptor positive allosteric modulator (PAM) in development for the treatment of schizophrenia, targeting a novel muscarinic receptor mechanism distinct from current antipsychotics.
• NMRA-215 A brain-penetrant, oral NLRP3 inhibitor in development for obesity, with potential for treatment of cardiometabolic disease, being evaluated both as monotherapy and in combination with existing GLP-1 therapies such as semaglutide.
• NMRA-GCASE A glucocerebrosidase (GCASE) activator in development for Parkinson's Disease, designed to increase glucocerebrosidase activity as a potential disease-modifying therapy.
• NMRA-CK1δ A CK1δ inhibitor in development for amyotrophic lateral sclerosis (ALS) and Parkinson's Disease, targeting casein kinase 1 delta to address neurodegenerative disease pathology.

Quantifiable outcome

• Navacaprant showed 15.7-point reduction on CMAI scale in Phase 1b for Alzheimer's agitation
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/NeumoraTx
• LinkedInlinkedin.com/company/neumora/about

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds5 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neumora Therapeutics